Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Human Ventricular Myosin Light Chain Isotype 1 as a Marker of Myocardial Injury

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          A monoclonal enzyme immunoassay for measuring human ventricular myosin light chain isotype 1 (HVMLC1) in serum has been developed. To evaluate the method in patients with suspected myocardial injury, we studied 51 patients (16 acute myocardial infarction (AMI), 19 unstable angina pectoris (UAP), 9 stable angina pectoris, 3 nonischemic heart disease, 4 hip surgery patients), and 190 controls (blood donors). Serial blood-samples were drawn from patients; a single blood-sample from controls. The diagnostic value of the HVMLC1 assay was compared with total creatine kinase (CK), CKMB activity, CKMB mass concentration, lactate dehydrogenase isoenzyme 1 (LD1), troponin T (TnT) and mitochondrial-aspartate aminotransferase (m-ASAT). The detection limit of HVMLC1 was 0.4 µg/l (linear range 0-20 µg/l). Sera from 190 reference persons did not contain detectable levels of HVMLC1 ( < 0.4 µg/l; 99% percentile). The coefficients of variation were 13% (1.0 µg/l) and 3.1% (17.7 µg/l). Cross-reactivity with myosin from skeletal muscle was seen. Times to peak value were: CK 19.3 ± 2.0, LD1 43.4 ± 3.2, HVMLC1 72.9 ± 7.0, and m-ASAT 67.3 ± 5.6 h. Time-curves of HVMLC1 and m-ASAT were similar, whereas time-curves for HVMLC 1 and TnT were quite different in most cases. Peak value of HVMLC 1 was five times higher than CK peak value and eight times that of LD1. HVMLC 1 appeared in the blood within hours after the onset of chest pain and in the majority remained for more than a week after AMI. Among patients with UAP 16% (3/19) had elevated HVMLC1 in serum, whereas elevated TnT was seen in 26% (5/19) and elevated CKMB mass in 26% (5/19). We conclude that the new HVMLC 1 assay offers a sensitive diagnosis of myocardial injury. It is characterized by a wide diagnostic time window. The similarity of the HVMLC 1 and m-ASAT curves indicates that it may be used to estimate the extent of myocardial necrosis.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          0008-6312
          1421-9751
          1994
          1994
          18 November 2008
          : 84
          : 2
          : 135-144
          Affiliations
          aDepartment of Medicine and Cardiology, Aarhus University Hospital, Aarhus, bDepartment of Clinical Chemistry, Odense University Hospital, Odense, cBioscience, Novo-Nordisk Industry A/S, Bagsværd, Denmark; dWadsworth Center for Laboratories and Research, New York State Department of Health, Albany, N.Y., USA
          Article
          176532 Cardiology 1994;84:135–144
          10.1159/000176532
          8174143
          © 1994 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 10
          Categories
          Coronary Care

          Comments

          Comment on this article